Program
lenvatinib
Also written as “Lenvatinib”, “E7080” and “HOPE”.
Its studies are mostly in Carcinoma, Hepatocellular · Melanoma · Thyroid Neoplasms · Carcinoma, Non-Small-Cell Lung · Carcinoma, Renal Cell, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eisai | 511 open or running | phase 4since Jun 19, 2018 | Jul 15, 2005 | none ahead |
| Merck | 261 open or running | phase 3since Jan 22, 2019 | Aug 3, 2016 | Oct 22, 2027phase 2 · NCT02861573 |
| AGO Research | 11 open or running | phase 2since May 11, 2023 | May 11, 2023 | Oct 30, 2027phase 2 · NCT05903833 |
| Merck KGaA, Darmstadt, Germany | 10 open or running | phase 1since Oct 4, 2021 | Oct 4, 2021 | none ahead |
Also a collaborator on its studies: Ono Pharmaceutical, pharmabio-development-inc and quintiles-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 43 studies since Jan 2, 2013.
- Mar 4, 2020Phase 4 study in Carcinoma, HepatocellularEisai · NCT04297254 · 50 enrolled · India
- Mar 9, 20202 phase 2 studies in MelanomaMerck · NCT04305054, NCT04305041
- Jun 9, 20202 phase 2 studiesMerck · NCT04428151, NCT04447755
- Dec 4, 20202 phase 3 studiesMerck · NCT04662710, NCT04676412
- Jan 7, 2021Phase 2 study in Carcinoma, Renal CellMerck · NCT04704219 · 160 enrolled · United States, Australia, Canada and more
- Jan 19, 2021Phase 3 study in Parkinson Disease 4, Autosomal Dominant Lewy BodyMerck · NCT04716933 · 201 enrolled · China
- Feb 26, 2021Phase 3 study in Colorectal NeoplasmsMerck · NCT04776148 · 563 enrolled · United States, Argentina, Australia and more
- Apr 26, 2021Phase 3 study in Endometrial NeoplasmsMerck · NCT04865289 · 130 enrolled · China
- May 12, 2021Phase 3 study in MelanomaMerck · NCT04889118 · 131 enrolled · China
- Jun 9, 2021Phase 2 study in Small Cell Lung CarcinomaMerck · NCT04924101 · 122 enrolled · United States, Austria, Canada and more
- Jun 29, 2021Phase 3 study in Esophageal Squamous Cell CarcinomaMerck · NCT04949256 · 863 enrolled · United States, Argentina, Canada and more
- Oct 4, 2021Merck KGaA, Darmstadt, Germany's first study: phase 1 study in Central Nervous System NeoplasmsNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT05081180 · 17 enrolled · Canada, France, Germany and more
- Aug 29, 2022Phase 3 study in Squamous Cell Carcinoma of Head and NeckMerck · NCT05523323 · 112 enrolled · China
- May 11, 2023AGO Research's first study: phase 2 study in Vulvar NeoplasmsNew to AGO ResearchAGO Research · NCT05903833 · 42 planned · Germany
Ahead
- Oct 22, 2027Primary completion: phase 2 study in Metastatic Castration-Resistant Prostate CancerMerck · NCT02861573
- Oct 30, 2027Primary completion: phase 2 study in Vulvar NeoplasmsAGO Research · NCT05903833
TargetBeta
“A synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase ”NCIt, by rule
“Vascular endothelial growth factor receptor inhibitor”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| regorafenibrule | Bayer | phase 4 | 40 |
| Axitinibrule | Pfizer | phase 3 | 45 |
| chiauranibrule | Chipscreen Biosciences | phase 3 | 15 |
Studies
The newest 60 of 79 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT05903833Vulvar Neoplasms · Germany | 2 | Recruiting | AGO Research | Oct 30, 2027 | 42 |
| NCT05523323Squamous Cell Carcinoma of Head and Neck · China | 3 | Completed | Merck | Aug 25, 2023 | 112 |
| NCT05081180Central Nervous System Neoplasms · Canada, France, Germany and more | 1 | Terminated | Merck KGaA, Darmstadt, Germany | Feb 11, 2026 | 17 |
| NCT04949256Esophageal Squamous Cell Carcinoma · United States, Argentina, Canada and more | 3 | Terminated | Merck | May 8, 2025 | 863 |
| NCT04924101Small Cell Lung Carcinoma · United States, Austria, Canada and more | 2 | Completed | Merck | Jun 23, 2025 | 122 |
| NCT04889118Melanoma · China | 3 | Completed | Merck | Jan 18, 2023 | 131 |
| NCT04865289Endometrial Neoplasms · China | 3 | Completed | Merck | Oct 2, 2023 | 130 |
| NCT04776148Colorectal Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Merck | Sep 27, 2024 | 563 |
| NCT04716933Parkinson Disease 4, Autosomal Dominant Lewy Body · China | 3 | Completed | Merck | Aug 11, 2023 | 201 |
| NCT04704219Carcinoma, Renal Cell · United States, Australia, Canada and more | 2 | Completed | Merck | Jan 27, 2025 | 160 |
| NCT04676412Carcinoma, Non-Small-Cell Lung · China | 3 | Completed | Merck | May 19, 2021 | 107 |
| NCT04662710Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Argentina, Australia and more | 3 | Completed | Merck | Oct 29, 2024 | 895 |
| NCT04447755Recurrence · United States, Argentina, Australia and more | 2 | Completed | Merck | Sep 16, 2022 | 127 |
| NCT04428151Squamous Cell Carcinoma of Head and Neck · United States, Australia, Brazil and more | 2 | Completed | Merck | May 31, 2024 | 408 |
| NCT04305054Melanoma · United States, Argentina, Australia and more | 2 | Completed | Merck | May 18, 2026 | 335 |
| NCT04305041Melanoma · United States, Australia, France and more | 2 | Completed | Merck | Aug 25, 2025 | 100 |
| NCT04297254Carcinoma, Hepatocellular · India | 4 | Completed | Eisai | Jul 31, 2023 | 50 |
| NCT04246177Carcinoma, Hepatocellular · United States, Australia, Brazil and more | 3 | Terminated | Merck | Aug 19, 2025 | 480 |
| NCT04199104Squamous Cell Carcinoma of Head and Neck · United States, Australia, Brazil and more | 3 | Completed | Merck | May 30, 2023 | 511 |
| NCT04154189Osteosarcoma · United States, Australia, Austria and more | 2 | Completed | Eisai | Jun 22, 2022 | 81 |
| NCT03976375Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Completed | Merck | Aug 11, 2023 | 422 |
| NCT03898180Carcinoma, Transitional Cell · United States, Argentina, Australia and more | 3 | Completed | Merck | Jul 26, 2021 | 505 |
| NCT03884101Endometrial Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Merck | Oct 2, 2023 | 842 |
| NCT03829332Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more | 3 | Completed | Merck | May 19, 2021 | 623 |
| NCT03829319Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Argentina, Australia and more | 3 | Completed | Merck | Aug 11, 2023 | 761 |
| NCT03820986Melanoma · United States, Australia, Austria and more | 3 | Completed | Merck | Jan 18, 2023 | 674 |
| NCT03797326Triple Negative Breast Neoplasms · United States, Argentina, Australia and more | 2 | Completed | Merck | Oct 28, 2024 | 611 |
| NCT03776136Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Australia, Canada and more | 2 | Completed | Merck | Oct 11, 2023 | 103 |
| NCT03573960Thyroid Neoplasms · India | 4 | Completed | Eisai | Sep 4, 2025 | 50 |
| NCT03516981Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Australia, Canada and more | 2 | Completed | Merck | Jun 13, 2025 | 245 |
| NCT03517449Endometrial Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Eisai | Mar 1, 2022 | 827 |
| NCT03477175Solid Tumors · United States, Australia, Belgium and more | 2 | Completed | Eisai | Dec 21, 2023 | 40 |
| NCT03433703Carcinoma, Hepatocellular · United States | 2 | Terminated | Eisai | Jan 7, 2019 | 8 |
| NCT03418922Carcinoma, Hepatocellular · Japan | 1 | Completed | Eisai | Dec 28, 2022 | 30 |
| NCT03245151Recurrence · United States, Canada | 2 | Completed | Eisai | Sep 30, 2022 | 64 |
| NCT03173560Carcinoma, Renal Cell · United States, Australia, Canada and more | 2 | Completed | Eisai | Feb 14, 2020 | 343 |
| NCT03009292Solid Tumor · China | 1 | Completed | Eisai | Dec 24, 2018 | 12 |
| NCT03006926Carcinoma, Hepatocellular · United States, France, Italy and more | 1 | Completed | Eisai | Oct 31, 2019 | 104 |
| NCT03006887Carcinoma, Non-Small-Cell Lung · Japan | 1 | Completed | Eisai | Apr 15, 2020 | 6 |
| NCT02966093Differentiated Thyroid Cancer (DTC) · China | 3 | Completed | Eisai | Jul 31, 2019 | 151 |
| NCT02953743Unresectable Hepatocellular Carcinoma (HCC) · China | 1 | Completed | Eisai | Jun 28, 2017 | 25 |
| NCT02915783Neoplasm Metastasis · United States | 2 | Completed | Eisai | Nov 2, 2021 | 41 |
| NCT02861573Metastatic Castration-Resistant Prostate Cancer | 2 | Active, not recruiting | Merck | Oct 22, 2027 | 1,200 |
| NCT02811861Carcinoma, Renal Cell · United States, Australia, Austria and more | 3 | Active, not recruiting | Eisai | Aug 28, 2020 | 1,069 |
| NCT02702388Thyroid Neoplasms · United States, Australia, Belgium and more | 2 | Completed | Eisai | Dec 12, 2019 | 241 |
| NCT02686164Neoplasms · United States | 1 | Completed | Eisai | Jan 4, 2017 | 51 |
| NCT02657369Thyroid Carcinoma, Anaplastic · United States, Australia, France and more | 2 | Terminated | Eisai | Sep 26, 2018 | 34 |
| NCT02579616Biliary Tract Neoplasms · Japan | 2 | Completed | Eisai | Nov 22, 2016 | 29 |
| NCT02792829Healthy Volunteers · United States | 1 | Completed | Eisai | Aug 2014 | 60 |
| NCT02723630Healthy Volunteers · United States | 1 | Completed | Eisai | Aug 2013 | 60 |
| NCT02578316Lymphoma · Netherlands | 1 | Completed | Eisai | Jun 2010 | 6 |
| NCT02501096Neoplasms · United States, Norway, Spain | 2 | Completed | Eisai | Aug 18, 2020 | 357 |
| NCT02454478Carcinoma, Renal Cell · Japan | 1 | Completed | Eisai | May 29, 2017 | 7 |
| NCT02432274Neoplasms · United States, France, Germany and more | 2 | Completed | Eisai | Jul 18, 2019 | 117 |
| NCT02421042Hepatic Impairment · United States | 1 | Completed | Eisai | Jul 2012 | 14 |
| NCT02199392P-glycoprotein · United States | 1 | Completed | Eisai | Jan 2012 | 15 |
| NCT02199379Renal Insufficiency · United States | 1 | Completed | Eisai | Oct 2012 | 26 |
| NCT02198170Healthy Volunteers · United States | 1 | Completed | Eisai | Jun 2011 | 18 |
| NCT01877083Lung Neoplasms · United States, Hong Kong, Japan and more | 2 | Completed | Eisai | Feb 3, 2016 | 25 |
| NCT01761266Carcinoma, Hepatocellular · United States, Australia, Belgium and more | 3 | Completed | Eisai | Nov 13, 2016 | 954 |
How it is read
Names in the registry
- “Lenvatinib”, 72 entries
- “lenvatinib”, 7 entries
- “E7080”, 6 entries
- “HOPE”, 2 entries
- “E7080 capsule”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Hepatocellular, 10 studies
- Melanoma, 7 studies
- Thyroid Neoplasms, 6 studies
- Carcinoma, Non-Small-Cell Lung, 6 studies
- Carcinoma, Renal Cell, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.